GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NovoCure Ltd (STU:038) » Definitions » Scaled Net Operating Assets

NovoCure (STU:038) Scaled Net Operating Assets : 0.07 (As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is NovoCure Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NovoCure's operating assets for the quarter that ended in Mar. 2024 was €231.2 Mil. NovoCure's operating liabilities for the quarter that ended in Mar. 2024 was €153.5 Mil. NovoCure's Total Assets for the quarter that ended in Dec. 2023 was €1,051.0 Mil. Therefore, NovoCure's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2024 was 0.07.


NovoCure Scaled Net Operating Assets Historical Data

The historical data trend for NovoCure's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NovoCure Scaled Net Operating Assets Chart

NovoCure Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Scaled Net Operating Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.17 0.15 0.05 0.05 0.04

NovoCure Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.05 0.05 0.06 0.04 0.07

Competitive Comparison of NovoCure's Scaled Net Operating Assets

For the Medical Devices subindustry, NovoCure's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NovoCure's Scaled Net Operating Assets Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NovoCure's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where NovoCure's Scaled Net Operating Assets falls into.



NovoCure Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

NovoCure's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Dec. 2023 is calculated as

Scaled Net Operating Assets (SNOA)(A: Dec. 2023 )
=(Operating Assets (A: Dec. 2023 )-Operating Liabilities (A: Dec. 2023 ))/Total Assets (A: Dec. 2022 )
=(215.965-171.837)/1124.916
=0.04

where

Operating Assets(A: Dec. 2023 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1051 - 835.035
=215.965

Operating Liabilities(A: Dec. 2023 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=718.591 - 546.754 - 0
=171.837

NovoCure's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2024 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2024 )
=(Operating Assets (Q: Mar. 2024 )-Operating Liabilities (Q: Mar. 2024 ))/Total Assets (Q: Dec. 2023 )
=(231.18-153.469)/1051
=0.07

where

Operating Assets(Q: Mar. 2024 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=1031.715 - 800.535
=231.18

Operating Liabilities(Q: Mar. 2024 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=701.108 - 547.639 - 0
=153.469

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


NovoCure Scaled Net Operating Assets Related Terms

Thank you for viewing the detailed overview of NovoCure's Scaled Net Operating Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


NovoCure (STU:038) Business Description

Traded in Other Exchanges
Address
Grenville Street, No. 4 The Forum, Second Floor, St. Helier, JEY, JE2 4UF
NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Ovarian Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, and Brain Metastasis. Products are comprised of two main components: electric field generator and arrays and related accessories. NovoCure derives its major revenues in the United States.

NovoCure (STU:038) Headlines

No Headlines